Arvinas, Inc.

NASDAQ:ARVN

Biotechnology

Healthcare
$6.77 -1.30%

-$0.10 today

Market cap
$443.01M
Beta
1.75
P/E (TTM)
-2.2
EPS (TTM)
-$3.46
52W Low $6.06High $14.51

Volume 1.09M

Average 0.89M

ARVN Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Arvinas, Inc.NASDAQ: ARVN

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 92.9%

Gross margin was 92.9% in Q1 FY2026, down 7.1 pp from a year earlier. On a trailing-twelve-month basis it was 97.4%, down 2.2 pp year over year. Over 3 fiscal years it narrowed by 2.0 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
92.9%+5.6 pp QoQ
Last fiscal yearDec 2025
98.0%-2.0 pp YoY
LTMMar 2026
97.4%-2.2 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-7.1 pp——
1 year-2.0 pp——
3 years-2.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
98.0%
Year-over-year change
-2.0pp

Gross Margin vs competitors

How ARVN compares with its peers on the latest reported figures

  • ARVN's LTM Mar 2026 gross margin of 97.4% is the 2nd highest of the 6 companies compared; the peer median is 94.8%.
  • Its year-over-year change of -2.2 pp is the 4th highest of 6, against a peer median of +6.6 pp.
  • Over three fiscal years its change of -2.0 pp compares with a peer median of -5.4 pp.
ARVN Competitors Peer median
Gross Margin for ARVN and competitors
Company Period LTM level YoY 3-year change
KYMRKymera Therapeutics, Inc.LTM Jun 2026102.0% +6.6 pp+0.0 pp
ARVNArvinas, Inc.LTM Mar 202697.4% -2.2 pp-2.0 pp
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 202695.3% -3.4 pp—
CCCCC4 Therapeutics, Inc.LTM Mar 202694.8% +9.6 pp-22.2 pp
NRIXNurix Therapeutics, Inc.LTM Aug 202686.5% +249.4 pp+455.2 pp
FHTXFoghorn Therapeutics Inc.LTM Mar 202622.3% -77.7 pp-10.8 pp
Peer median (excluding ARVN) 94.8%+6.6 pp-5.4 pp

Competitors are the stored peer set for ARVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue53.6M131.4M78.5M263.4M262.6M
Cost of Revenue00005.2M
Gross Profit53.6M131.4M78.5M263.4M257.4M
Gross Margin100.0%100.0%100.0%100.0%98.0%
Research & Development180.4M315M379.7M348.2M282.9M
Selling, General & Admin61.6M79.6M100.3M165.4M89.4M
Operating Expenses242M394.6M480M513.6M372.3M
Depreciation & Amortization6M8.2M6.7M6.6M5.2M
EBITDA(184.9M)(253.4M)(359.7M)(191.7M)(75.3M)
EBITDA Margin-345.0%-192.8%-458.2%-72.8%-28.7%
Operating Income(188.4M)(263.2M)(401.5M)(250.2M)(114.9M)
Operating Margin-351.5%-200.3%-511.5%-95.0%-43.8%
Interest Income1.8M12M38.8M54.8M22M
Interest Expense100K0000
Other Income / Expenses(2.6M)1.6M35.1M51.9M34.4M
Income Before Tax(191M)(261.6M)(366.4M)(198.3M)(80.5M)
Pre-Tax Margin-356.3%-199.1%-466.8%-75.3%-30.7%
Income Tax Expense020.9M900K600K300K
Net Income(191M)(282.5M)(367.3M)(198.9M)(80.8M)
Net Margin-356.3%-215.0%-467.9%-75.5%-30.8%
EPS (Basic)(3.82)(5.31)(6.62)(2.77)(1.28)
EPS (Diluted)(3.82)(5.31)(6.62)(2.77)(1.28)
Weighted Avg Shares50M53.2M55.5M71.9M64.9M
Weighted Avg Shares (Diluted)50M53.2M55.5M71.9M64.9M

Arvinas, Inc.

NASDAQ:ARVN

Intrinsic Alpha fair value

Locked

Current Price

$6.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.